Ranked #1
Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma
Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma
At ASCO 2014, Dr O'Day provides ecancertv with his expert opinion on the findings from a large phase I study of 411 pati... Read more
15 Jul 2014
•
1min
Ranked #2
ASCO 2014 roundup
ASCO 2014 roundup
ecancer's Prof McVie provides a roundup of the main points of discussion from ASCO 2014.
11 Jul 2014
•
12mins
Similar Podcasts
2013 ASCO Annual Meeting
2013 NMC Summer Conference
Energy - Delivering a Secure & Sustainable Supply for the Future
2015 Abedian School of Architecture Lecture Series
Artificial Intelligence
Ranked #3
KRAS/NRAS and BRAF mutations in study of panitumumab plus FOLFIRI for second-line treatment of mCC
KRAS/NRAS and BRAF mutations in study of panitumumab plus FOLFIRI for second-line treatment of mCC
Prof Peeters talks to ecancertv at ASCO 2014 about the updated analysis of KRAS/NRAS and BRAF mutations in study 2005018... Read more
11 Jul 2014
•
2mins
Ranked #4
HPV-targeted adoptive T Cell therapy for advanced cervical cancer
HPV-targeted adoptive T Cell therapy for advanced cervical cancer
Dr Hinrichs talks to ecancertv at ASCO 2014 about his work using immunotherapy to tackle cervical cancer. HPV-targeted t... Read more
8 Jul 2014
•
5mins
Most Popular Podcasts
The Joe Rogan Experience
TED Talks Daily
The Tim Ferriss Show
The Daily
Stuff You Should Know
Oprah's SuperSoul Conversations
Armchair Expert with Dax Shepard
Ranked #5
Adjuvant exemestane more effective than tamoxifen if combined with ovarian function suppression in breast cancer
Adjuvant exemestane more effective than tamoxifen if combined with ovarian function suppression in breast cancer
Dr Pagani talks to ecancertv at ASCO 2014 about the results of a landmark study that was a joint analysis of two phase I... Read more
8 Jul 2014
•
5mins
Ranked #6
Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL
Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL
Dr Byrd talks to ecancertv at ASCO 2014 about the early findings from the phase III RESONATE study which indicate that i... Read more
8 Jul 2014
•
4mins
Ranked #7
Comment: Immunotherapy combo increases median survival in advanced melanoma
Comment: Immunotherapy combo increases median survival in advanced melanoma
At ASCO 2014, Dr O'Day provides ecancertv with his expert opinion on the results from an expanded phase I study which sh... Read more
8 Jul 2014
•
3mins
Ranked #8
T-VEC injections into melanoma lesions show significant response rate
T-VEC injections into melanoma lesions show significant response rate
Prof Harrington talks to ecancertv at ASCO 2014 about a randomised phase III trial of talimogene laherparepvec (T-VEC) v... Read more
8 Jul 2014
•
8mins
Ranked #9
Inhibition of PD-L1 using drug MPDL3280A for patients with metastatic urothelial bladder cancer
Inhibition of PD-L1 using drug MPDL3280A for patients with metastatic urothelial bladder cancer
Prof Thomas Powles (Barts Health, London, UK) discusses the use of the drug MPDL3280A to inhibit the protein PD-L1 in pa... Read more
8 Jul 2014
•
5mins
Ranked #10
Ramucirumab plus docetaxel extends survival in advanced NSCLC
Ramucirumab plus docetaxel extends survival in advanced NSCLC
Dr Pérol talks to ecancertv at ASCO 2014 about the findings from the REVEL phase III study of patients with stage IV non... Read more
8 Jul 2014
•
3mins
